Artivion, Inc. $AORT Shares Bought by Russell Investments Group Ltd.

Russell Investments Group Ltd. grew its position in Artivion, Inc. (NYSE:AORT) by 17.5% during the 1st quarter, HoldingsChannel.com reports. The fund owned 169,594 shares of the company’s stock after buying an additional 25,234 shares during the quarter. Russell Investments Group Ltd.’s holdings in Artivion were worth $4,169,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Public Sector Pension Investment Board lifted its position in Artivion by 27.4% during the first quarter. Public Sector Pension Investment Board now owns 119,650 shares of the company’s stock worth $2,941,000 after buying an additional 25,698 shares in the last quarter. Nuveen LLC purchased a new position in Artivion during the first quarter worth approximately $2,653,000. Invesco Ltd. lifted its position in Artivion by 27.9% during the first quarter. Invesco Ltd. now owns 341,656 shares of the company’s stock worth $8,398,000 after buying an additional 74,589 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in Artivion by 5.0% during the first quarter. Charles Schwab Investment Management Inc. now owns 376,052 shares of the company’s stock worth $9,243,000 after buying an additional 17,860 shares in the last quarter. Finally, Natixis Advisors LLC lifted its position in Artivion by 16.4% during the first quarter. Natixis Advisors LLC now owns 12,615 shares of the company’s stock worth $310,000 after buying an additional 1,777 shares in the last quarter. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Artivion Trading Up 3.9%

AORT opened at $44.8140 on Friday. Artivion, Inc. has a 12 month low of $21.97 and a 12 month high of $45.07. The stock has a market capitalization of $2.11 billion, a price-to-earnings ratio of -106.70 and a beta of 1.64. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.78 and a quick ratio of 3.48. The business has a fifty day moving average price of $33.65 and a 200 day moving average price of $28.87.

Artivion (NYSE:AORT) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.13. The business had revenue of $112.97 million during the quarter, compared to analysts’ expectations of $107.96 million. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The firm’s quarterly revenue was up 15.3% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. Sell-side analysts expect that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

AORT has been the topic of a number of research analyst reports. JMP Securities lifted their target price on Artivion from $33.00 to $42.00 and gave the company a “market outperform” rating in a research report on Friday, August 8th. Stifel Nicolaus lifted their target price on Artivion from $36.00 to $40.00 and gave the company a “buy” rating in a research report on Friday, August 8th. Needham & Company LLC lifted their target price on Artivion from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Friday. Canaccord Genuity Group lifted their target price on Artivion from $35.00 to $41.00 and gave the company a “buy” rating in a research report on Friday, August 8th. Finally, LADENBURG THALM/SH SH downgraded Artivion from a “buy” rating to a “neutral” rating and lifted their target price for the company from $32.00 to $38.80 in a research report on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $40.63.

Insider Transactions at Artivion

In other news, CEO James P. Mackin sold 12,500 shares of the business’s stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $42.32, for a total value of $529,000.00. Following the completion of the sale, the chief executive officer directly owned 852,783 shares of the company’s stock, valued at approximately $36,089,776.56. The trade was a 1.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider John E. Davis sold 10,802 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $43.67, for a total value of $471,723.34. Following the sale, the insider directly owned 208,778 shares of the company’s stock, valued at approximately $9,117,335.26. This represents a 4.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 96,538 shares of company stock valued at $3,444,651 over the last quarter. Company insiders own 7.60% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.